Dilution profile // every instrument, one screen, from SEC filings

BetterLife Pharma Inc. (BETRF)

CIK 1464165 · all EDGAR filings →

Overall dilution risk
HIGHworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
HIGHS-1/A on file 2010-03-16
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
LOWwarrants = 10% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
MEDIUM+34% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
a reverse-split-sized cliff is in this window; read the chart
Cash need
MEDIUM~12.3 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2015-05-152025-05-30

Latest: 145.5M shares as of May 30, 2025 (20-F). Share count fell from 172.1M to 51.4M between Jan 31, 2020 and Jan 31, 2021, a pattern consistent with a reverse split (roughly 1-for-3); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Funded — but tight

~12 months of cash · watch

Full breakdown: cash runway tool · source filing →

Warrants

Warrants outstanding: 15.2M underlying shares, as reported Apr 30, 2019 (10-Q).

Reported exercise price: $0.42 (aggregate figure as tagged; individual tranches vary).

Rough fully diluted estimate: 160.7M = 145.5M O/S + 15.2M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

The latest 10-Q/10-K instance document could not be checked just now, so nothing is shown rather than guessed. Try again shortly.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding145.5MMay 30, 2025
+ Warrants (aggregate, as tagged) (if exercised)15.2MApr 30, 2019
Fully diluted estimate160.7M+10.5% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

Last 12 months: 0 executed · 0 registered.

EXECUTEDMay 21, 2019Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDFeb 4, 2019Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDNov 6, 2018Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDSep 18, 2018Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDMar 12, 2018Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDDec 19, 2017Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDNov 23, 2015Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDJul 30, 2015Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDMar 26, 2015Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDAug 29, 2011Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDAug 12, 2010Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDJun 1, 2010Unregistered share sale disclosed (8-K item 3.02)8-K

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full BETRF workspace